Radius Health Stock Drops After EMERALD Trial Results at San Antonio Breast Cancer Symposium 2021

Dec 8, 2021 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot

Cancer Research

Radius Health, Inc. (NASDAQ: RDUS) shares dropped more than 40% after the biopharmaceutical Company announced details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.

Phase 3 Trial

The EMERALD trial (NCT03778931), a multicenter, international, randomized, open-label, controlled phase 3 trial evaluated elacestrant as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC. Radius explained that the trail enrolled patients who had previously received 1 or 2 lines of endocrine therapy (ET). In addition, prior progression on an ET plus CDK4/6 inhibitors was mandated for all patients. 

Potential for New Standard

Dr. Aditya Bardia, MD, breast medical oncologist at Mass General Cancer Center, Harvard Medical School and principal investigator of EMERALD, commented, “Patients with pre-treated ER+/HER2- advanced or metastatic breast cancer currently have limited treatment options due to the development of endocrine therapy resistance from earlier treatment lines.” Dr. Bardia continued, “Elacestrant – as the first oral SERD – has the potential to become the new standard of care given its performance vs. intramuscular fulvestrant and SoC in the overall population and in the ESR1 patient subgroup. As an oral monotherapy, elacestrant will offer patients, their families, and healthcare providers an efficacious and safe treatment option going forward.”

Trial a Success

The trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population.

Support for Women with Osteoporosis

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis.